Attention Deficit Hyperactivity Disorder in Neurofibromatosis Type 1: Evaluation with a Continuous Performance Test
- PMID: 29629523
- PMCID: PMC5897196
- DOI: 10.3988/jcn.2018.14.2.153
Attention Deficit Hyperactivity Disorder in Neurofibromatosis Type 1: Evaluation with a Continuous Performance Test
Abstract
Background and purpose: The objective of this study was to determine if the MOXO visual- and vocal-distractors-based continuous performance test distinguishes patients with attention deficit hyperactivity disorder (ADHD) and neurofibromatosis type 1 (NF1) from those without NF1.
Methods: Thirty-five patients (16 males; mean age 9.91 years) attending a multidisciplinary NF1 clinic completed the MOXO test. The findings were compared to 532 healthy age-matched standardized control subjects (285 males) without ADHD.
Results: The overall performance in the MOXO text was significantly worse in the NF1 group than in controls (p<0.01), but no group-specific pattern was identified. Impulsivity and hyperactivity were significantly more prominent in males than females (p<0.01). Compared to controls, the NF1 group exhibited significantly more failures to respond to target stimuli in the presence of visual distractors.
Conclusions: MOXO scores are abnormal in patients with NF1, but the test cannot differentiate between NF1 with ADHD characteristics and ADHD. The test highlights sex differences in ADHD characteristics in NF1. Overreactivity to visual distractors may form part of the attention deficit in NF1.
Keywords: MOXO; attention deficit hyperactivity disorder; continuous performance test; neurofibromatosis type 1.
Copyright © 2018 Korean Neurological Association.
Conflict of interest statement
The authors have no financial conflicts of interest.
Figures
Similar articles
-
Utility of continuous performance test (MOXO-CPT) in children with pre-dialysis chronic kidney disease, dialysis and kidney transplantation.J Nephrol. 2022 Sep;35(7):1873-1883. doi: 10.1007/s40620-022-01382-1. Epub 2022 Jul 23. J Nephrol. 2022. PMID: 35871244
-
Detection of Feigned ADHD Using the MOXO-d-CPT.J Atten Disord. 2021 May;25(7):1032-1047. doi: 10.1177/1087054719864656. Epub 2019 Jul 31. J Atten Disord. 2021. PMID: 31364437
-
Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?Dev Med Child Neurol. 2012 Oct;54(10):898-904. doi: 10.1111/j.1469-8749.2012.04357.x. Epub 2012 Jul 28. Dev Med Child Neurol. 2012. PMID: 22845611
-
Usefulness and Validity of Continuous Performance Tests in the Diagnosis of Attention-Deficit Hyperactivity Disorder Children.Arch Clin Neuropsychol. 2017 Feb;32(1):81-93. doi: 10.1093/arclin/acw101. Epub 2016 Nov 23. Arch Clin Neuropsychol. 2017. PMID: 28122767
-
Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1.Front Pediatr. 2017 Oct 30;5:227. doi: 10.3389/fped.2017.00227. eCollection 2017. Front Pediatr. 2017. PMID: 29164079 Free PMC article. Review.
Cited by
-
Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1.Neurol Clin Pract. 2021 Dec;11(6):497-505. doi: 10.1212/CPJ.0000000000001089. Neurol Clin Pract. 2021. PMID: 34987881 Free PMC article.
-
Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.JAMIA Open. 2025 Jan 22;8(1):ooae157. doi: 10.1093/jamiaopen/ooae157. eCollection 2025 Feb. JAMIA Open. 2025. PMID: 39845289 Free PMC article.
-
Neurobehavioral sex-related differences in Nf1+/- mice: female show a "camouflaging"-type behavior.Biol Sex Differ. 2023 Apr 26;14(1):24. doi: 10.1186/s13293-023-00509-8. Biol Sex Differ. 2023. PMID: 37101298 Free PMC article.
-
Increased Prevalence of Psychiatric Disorders in Children with RASopathies: Comparing NF1, Noonan Syndrome Spectrum Disorder, and the General Population.Genes (Basel). 2025 Jul 19;16(7):843. doi: 10.3390/genes16070843. Genes (Basel). 2025. PMID: 40725498 Free PMC article.
-
Attention-Deficit/Hyperactivity Disorder (ADHD): Integrating the MOXO-dCPT with an Eye Tracker Enhances Diagnostic Precision.Sensors (Basel). 2020 Nov 9;20(21):6386. doi: 10.3390/s20216386. Sensors (Basel). 2020. PMID: 33182303 Free PMC article.
References
-
- Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124–133. - PubMed
-
- Payne JM, Hyman SL, Shores EA, North KN. Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behavior. Child Neuropsychol. 2011;17:313–329. - PubMed
-
- Centers for Disease Control and Prevention (US) Attention Deficit Hyperactivity Disorder (ADHD) [Internet] Atlanta (GA): CDC/National Center for Health Statistics; 2017. [cited 2018 Feb]. Available from: https://www.cdc.gov/nchs/fastats/adhd.htm.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous